Zum Inhalt

HealthOSArzneimittel

Arbeitsbereiche

Nachschlagen

Wirkstoffe & Arzneimittelsicherheit

Exakte Wirkstoffkennungen und zitierbare Passagen zu Wechselwirkungen, Gegenanzeigen und Nebenwirkungen.

Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.

RxNorm 05-Oct-2026 · geprüft 2026-10-27 · 1381 Präparate · 72104 Quellenpassagen · 204 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.

Quellenpassagen (1)

Wechselwirkungen · Epclusa

Epclusa 400 mg/100 mg film-coated tablets Epclusa 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 12–13

HOS-136150 · Präparat HOS-097846

12 Medicinal product by Effects on medicinal product levels. therapeutic areas/Possible Mean ratio (90% confidence interval)a,b Recommendation concerning Mechanism of Interaction Active Cmax AUC Cmin co-administration with Epclusa HMG-CoA REDUCTASE INHIBITORS Atorvastatin (40 mg single Observed: ↑ ↑ No dose adjustment of Epclusa or dose) + sofosbuvir / Atorvastatin 1.7 1.5 atorvastatin is required. velpatasvir (400/ 100 mg (1.5, (1.5, once daily)d 1.9) 1.6) Rosuvastatin Interaction only studied with velpatasvir Co-administration of Epclusa with Expected: rosuvastatin increases the ↔ Sofosbuvir concentration of rosuvastatin, Rosuvastatin (10 mg single Observed: which is associated with increased dose)/ velpatasvir (100 mg Rosuvastatin ↑ ↑ risk of myopathy, including once daily)d 2.6 2.7 rhabdomyolysis. Rosuvastatin, at a (2.3, (2.5, dose that does not exceed 10 mg, 2.9) 2.9) may be administered with Epclusa. Effect on velpatasvir exposure not studied (Inhibition of OATP1B and Expected: BCRP) ↔ Velpatasvir Pravastatin Interaction only studied with velpatasvir No dose adjustment of Epclusa or Expected: pravastatin is required. ↔ Sofosbuvir Pravastatin (40 mg single Observed: dose)/ velpatasvir (100 mg Pravastatin ↑ ↑ once daily)d 1.3 1.4 (1.1, (1.2, 1.5) 1.5) (Inhibition of OATP1B) Effect on velpatasvir exposure not studied Expected: ↔ Velpatasvir Other statins Expected: Interactions cannot be excluded ↑ Statins with other HMG-CoA reductase inhibitors. When co-administered with Epclusa, careful monitoring for statin adverse reactions should be undertaken and a reduced dose of statins should be considered if required. NARCOTIC ANALGESICS Methadone R-methadone ↔ ↔ ↔ No dose adjustment of Epclusa or (Methadone maintenance methadone is required. therapy [30 to 130 mg S-methadone ↔ ↔ ↔ daily])/ sofosbuvir (400 mg once daily)d Sofosbuvir ↔ ↑ 1.3 (1.0, 1.7) Methadone Interaction only studied with sofosbuvir Expected: ↔ Velpatasvir

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): methadone (HOS-086198) atorvastatin (HOS-086304) rosuvastatin (HOS-086307) pravastatin (HOS-086306)

Vollständigen Kontext in der EMA-Fachinformation lesen →
Quellennachweis

Version 2023-08-14T16:16:00Z · SHA-256 5a15459ef6523a9cfa2e141592af073eabefab68f2b8f9dc006f477858a7fe66 · Passage 5aed4ac1e6d217eb48d5dfb1317ab9fd16e24af41c521fed5d10de9460884ed7 · Zeichen 25141–28918 im Abschnitt

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.